Analysis of correlation between RASSF2A gene methylation and colorectal cancer

doi:10.3760/cma.j.issn.1673422X.2018.02.004

Abstract

Abstract: ObjectiveTo investigate the methylation status of RASSF2A gene promoter in colorectal cancer tissues and its correlation with the occurrence of colorectal. MethodsFrom February 2007 to March 2013, a total of 111 cases of sporadic colorectal cancer patients were selected. The methylation status of RASSF2A gene in tumor tissue and normal mucosa were detected by using combined bisulfite restriction endonuclease method (COBRA). The correlations between the methylation of RASSF2A gene and the clinicopathologic features of colorectal cancer were analyzed. ResultsMethylation of RASSF2A gene was found in 83.78% (93/111) and 7.21% (8/111) of colorectal cancer tissues and normal tissues, with statistically significant difference (χ2=131.245, P＜0.001). The methylation of RASFF2A gene was not correlated with histology type (χ2=3.554, P=0.314), Duke staging (χ2=3.217, P=0.359) and location of tumor (χ2=1.060, P=0.303). ConclusionThe presence of RASSF2A hypermethylation in colorectal cancer may be associated with the occurrence of colorectal cancer.

Key words: Colorectal neoplasms, DNA methylation, RASSF2A gene

An Liang, Li Jun, Chen Yuxiang, Fang Xiang. Analysis of correlation between RASSF2A gene methylation and colorectal cancer[J]. Journal of International Oncology, 2018, 45(2): 77-79.

References

［1］田筱青, 和水祥. 大肠癌中生长抑素基因甲基化研究［J］. 西安交通大学学报(医学版), 2012, 33(4): 515516. DOI: 10.3969/j.issn.16718259.2012.04.028. ［2］张玲, 盛树力, 秦川, 等. 表观遗传学药物的研究进展［J］. 中国药理学通报, 2013, 29(3): 297303. DOI: 10.3969/j.issn.10011978.2013.03.001. ［3］王瑞娴, 徐建红. 基因组DNA甲基化及组蛋白甲基化［J］. 遗传, 2014, 36(3): 191199. DOI: 10.3724/SP.J.1005.2014.0191. ［4］马腾飞, 韦达, 赵建华, 等. RASSF2A基因启动子甲基化与肿瘤关系的研究进展［J］. 国际检验医学杂志, 2014, 35(12): 15951597. DOI: 10.3969/j.issn.16734130.2014.12.031. ［5］涂敏松, 李逸松, 代晓明, 等. DNA甲基化与口腔鳞状细胞癌的相关性研究进展［J］. 国际口腔医学杂志, 2016, 43(1): 7984. DOI: 10.7518/gjkq.2016.01.020. ［6］常志伟, 秦艳茹, 宋敏, 等. 胃癌轴突导向受体蛋白2和Ras相关区域家族2A基因甲基化状态研究［J］. 中华实验外科杂志, 2014, 31(10): 22872289. DOI: 10.3760/cma.j.issn.10019030.2014.10.070. ［7］张娴, 张友忠. 宫颈癌RASSF2A基因启动子甲基化与其临床病理特征的关系［J］. 现代妇产科进展, 2014, 23(7): 524526. DOI: 10.13283/j.cnki.xdfckjz.2014.07.005. ［8］杨静, 季文樾, 曲亚荣, 等. 喉癌组织中RASSF1A基因的表达缺失与DNA甲基化和组蛋白修饰的关系［J］. 中华耳鼻咽喉头颈外科杂志, 2011, 46(4): 308312. DOI: 10.3760/cma.j.issn.16730860.2011.04.011. ［9］武玉, 路炜, 刘颖, 等. 上皮性卵巢癌RASSF2A基因甲基化及其表达的临床意义［J］. 中华肿瘤防治杂志, 2015, 22(20): 16091613. DOI: 10.3760/cma.j.issn.10069801.2016.09.007. ［10］马腾飞, 韦达, 钟山亮, 等. 5AzaCdR对乳腺癌MCF7细胞增殖及抑癌基因RASSF2A表达的影响［J］. 华中科技大学学报(医学版), 2015, 44(2): 152155. DOI: 10.3870/j.issn.16720741.2015.02.006. ［11］ Meng W, Huebner A, Shabsigh A, et al. Combined RASSF1A and RASSF2A promoter methylation analysis as diagnostic biomarker for bladder cancer［J］. Mol Biol Int, 2012, 2012: 701814. DOI: 10.1155/2012/701814. ［12］ Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif1 genes in plasma as a biomarker for early detection of colorectal cancer［J］. Clin Cancer Res, 2009, 15(19): 61856191. DOI: 10.1158/10780432.CCR090111.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu. Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment [J]. Journal of International Oncology, 2022, 49(8): 490-493.